Cargando…

Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance

Altered death receptor signaling and resistance to subsequent apoptosis is an important clinical resistance mechanism. Here, we investigated the role of death receptor resistance in breast cancer progression. Resistance of the estrogen receptor alpha (ER)-positive, chemosensitive MCF7 breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Antoon, James W., Lai, Rongye, Struckhoff, Amanda P., Nitschke, Ashley M., Elliott, Steven, Martin, Elizabeth C., Rhodes, Lyndsay V., Yoon, Nam Seung, Salvo, Virgilio A., Shan, Bin, Beckman, Barbara S., Nephew, Kenneth P., Burow, Matthew E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406343/
https://www.ncbi.nlm.nih.gov/pubmed/22844580
http://dx.doi.org/10.1038/srep00539
_version_ 1782239223867244544
author Antoon, James W.
Lai, Rongye
Struckhoff, Amanda P.
Nitschke, Ashley M.
Elliott, Steven
Martin, Elizabeth C.
Rhodes, Lyndsay V.
Yoon, Nam Seung
Salvo, Virgilio A.
Shan, Bin
Beckman, Barbara S.
Nephew, Kenneth P.
Burow, Matthew E.
author_facet Antoon, James W.
Lai, Rongye
Struckhoff, Amanda P.
Nitschke, Ashley M.
Elliott, Steven
Martin, Elizabeth C.
Rhodes, Lyndsay V.
Yoon, Nam Seung
Salvo, Virgilio A.
Shan, Bin
Beckman, Barbara S.
Nephew, Kenneth P.
Burow, Matthew E.
author_sort Antoon, James W.
collection PubMed
description Altered death receptor signaling and resistance to subsequent apoptosis is an important clinical resistance mechanism. Here, we investigated the role of death receptor resistance in breast cancer progression. Resistance of the estrogen receptor alpha (ER)-positive, chemosensitive MCF7 breast cancer cell line to tumor necrosis factor (TNF) was associated with loss of ER expression and a multi-drug resistant phenotype. Changes in three major pathways were involved in this transition to a multidrug resistance phenotype: ER, Death Receptor and epithelial to mesenchymal transition (EMT). Resistant cells exhibited altered ER signaling, resulting in decreased ER target gene expression. The death receptor pathway was significantly altered, blocking extrinsic apoptosis and increasing NF-kappaB survival signaling. TNF resistance promoted EMT changes, resulting in a more aggressive phenotype. This first report identifying specific mechanisms underlying acquired resistance to TNF could lead to a better understanding of the progression of breast cancer in response to chemotherapy treatment.
format Online
Article
Text
id pubmed-3406343
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-34063432012-07-27 Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance Antoon, James W. Lai, Rongye Struckhoff, Amanda P. Nitschke, Ashley M. Elliott, Steven Martin, Elizabeth C. Rhodes, Lyndsay V. Yoon, Nam Seung Salvo, Virgilio A. Shan, Bin Beckman, Barbara S. Nephew, Kenneth P. Burow, Matthew E. Sci Rep Article Altered death receptor signaling and resistance to subsequent apoptosis is an important clinical resistance mechanism. Here, we investigated the role of death receptor resistance in breast cancer progression. Resistance of the estrogen receptor alpha (ER)-positive, chemosensitive MCF7 breast cancer cell line to tumor necrosis factor (TNF) was associated with loss of ER expression and a multi-drug resistant phenotype. Changes in three major pathways were involved in this transition to a multidrug resistance phenotype: ER, Death Receptor and epithelial to mesenchymal transition (EMT). Resistant cells exhibited altered ER signaling, resulting in decreased ER target gene expression. The death receptor pathway was significantly altered, blocking extrinsic apoptosis and increasing NF-kappaB survival signaling. TNF resistance promoted EMT changes, resulting in a more aggressive phenotype. This first report identifying specific mechanisms underlying acquired resistance to TNF could lead to a better understanding of the progression of breast cancer in response to chemotherapy treatment. Nature Publishing Group 2012-07-27 /pmc/articles/PMC3406343/ /pubmed/22844580 http://dx.doi.org/10.1038/srep00539 Text en Copyright © 2012, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareALike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Article
Antoon, James W.
Lai, Rongye
Struckhoff, Amanda P.
Nitschke, Ashley M.
Elliott, Steven
Martin, Elizabeth C.
Rhodes, Lyndsay V.
Yoon, Nam Seung
Salvo, Virgilio A.
Shan, Bin
Beckman, Barbara S.
Nephew, Kenneth P.
Burow, Matthew E.
Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance
title Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance
title_full Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance
title_fullStr Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance
title_full_unstemmed Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance
title_short Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance
title_sort altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406343/
https://www.ncbi.nlm.nih.gov/pubmed/22844580
http://dx.doi.org/10.1038/srep00539
work_keys_str_mv AT antoonjamesw altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT lairongye altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT struckhoffamandap altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT nitschkeashleym altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT elliottsteven altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT martinelizabethc altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT rhodeslyndsayv altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT yoonnamseung altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT salvovirgilioa altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT shanbin altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT beckmanbarbaras altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT nephewkennethp altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance
AT burowmatthewe altereddeathreceptorsignalingpromotesepithelialtomesenchymaltransitionandacquiredchemoresistance